{"id":"cefoperazone-sodium-and-sulbactam-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefoperazone is a third-generation cephalosporin that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall. Sulbactam is a beta-lactamase inhibitor that irreversibly binds and inactivates many beta-lactamases, preventing enzymatic destruction of cefoperazone and extending its spectrum to include beta-lactamase-producing organisms. This combination is effective against gram-positive and gram-negative bacteria, including some anaerobes.","oneSentence":"Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:22.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections)"},{"name":"Polymicrobial infections including beta-lactamase-producing strains"}]},"trialDetails":[{"nctId":"NCT07118384","phase":"NA","title":"Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-05-01","conditions":"Acinetobacter Baumannii Infection","enrollment":50},{"nctId":"NCT06729619","phase":"","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","startDate":"2024-06-03","conditions":"Intracranial Infection, Central Infection","enrollment":200},{"nctId":"NCT05535309","phase":"","title":"Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2021-11-02","conditions":"Risk Factors","enrollment":8000},{"nctId":"NCT05654090","phase":"PHASE4","title":"Evaluate Bioequivalence of Burotam (1/1 g/Vial)","status":"UNKNOWN","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2022-08-25","conditions":"Infectious Diseases","enrollment":14},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03776409","phase":"","title":"Safety and Efficacy of Vancomycin Plus Beta-lactams","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-12-12","conditions":"Critical Illness","enrollment":700},{"nctId":"NCT01601093","phase":"PHASE2","title":"Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"SUSPENDED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-11","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":288},{"nctId":"NCT02060149","phase":"PHASE1, PHASE2","title":"The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2014-03","conditions":"Pneumonia","enrollment":90},{"nctId":"NCT00463762","phase":"","title":"Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2007-05","conditions":"Abscess, Intra-Abdominal, Cholecystitis, Wound Infections","enrollment":""},{"nctId":"NCT01280461","phase":"","title":"An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2010-07","conditions":"Pneumonia","enrollment":142},{"nctId":"NCT00360607","phase":"PHASE4","title":"A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Infection","enrollment":307}],"_emaApprovals":[],"_faersSignals":[{"count":18,"reaction":"HAEMOGLOBIN DECREASED"},{"count":16,"reaction":"LYMPHOCYTE COUNT DECREASED"},{"count":15,"reaction":"PNEUMONIA"},{"count":13,"reaction":"PLATELET COUNT DECREASED"},{"count":13,"reaction":"PYREXIA"},{"count":12,"reaction":"BLOOD UREA INCREASED"},{"count":12,"reaction":"DIARRHOEA"},{"count":12,"reaction":"NEUTROPHIL COUNT INCREASED"},{"count":12,"reaction":"URINARY TRACT INFECTION"},{"count":11,"reaction":"ANAEMIA"}],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"cefoperazone sodium and sulbactam sodium","genericName":"cefoperazone sodium and sulbactam sodium","companyName":"Yung Shin Pharm. Ind. Co., Ltd.","companyId":"yung-shin-pharm-ind-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections), Polymicrobial infections including beta-lactamase-producing strains.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}